JP2017535610A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535610A5
JP2017535610A5 JP2017545520A JP2017545520A JP2017535610A5 JP 2017535610 A5 JP2017535610 A5 JP 2017535610A5 JP 2017545520 A JP2017545520 A JP 2017545520A JP 2017545520 A JP2017545520 A JP 2017545520A JP 2017535610 A5 JP2017535610 A5 JP 2017535610A5
Authority
JP
Japan
Prior art keywords
carbons
compound according
linear
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017545520A
Other languages
English (en)
Japanese (ja)
Other versions
JP6637988B2 (ja
JP2017535610A (ja
Filing date
Publication date
Priority claimed from US14/546,105 external-priority patent/US9593077B2/en
Priority claimed from US14/707,876 external-priority patent/US9365610B2/en
Application filed filed Critical
Priority claimed from PCT/US2015/030218 external-priority patent/WO2016081029A1/en
Publication of JP2017535610A publication Critical patent/JP2017535610A/ja
Publication of JP2017535610A5 publication Critical patent/JP2017535610A5/ja
Application granted granted Critical
Publication of JP6637988B2 publication Critical patent/JP6637988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017545520A 2014-11-18 2015-05-11 Rna送達のためのイオン化可能カチオン性脂質 Active JP6637988B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/546,105 2014-11-18
US14/546,105 US9593077B2 (en) 2013-11-18 2014-11-18 Ionizable cationic lipid for RNA delivery
US14/707,876 US9365610B2 (en) 2013-11-18 2015-05-08 Asymmetric ionizable cationic lipid for RNA delivery
US14/707,796 2015-05-08
US14/707,796 US9567296B2 (en) 2013-11-18 2015-05-08 Ionizable cationic lipid for RNA delivery
US14/707,876 2015-05-08
PCT/US2015/030218 WO2016081029A1 (en) 2014-11-18 2015-05-11 Ionizable cationic lipid for rna delivery

Publications (3)

Publication Number Publication Date
JP2017535610A JP2017535610A (ja) 2017-11-30
JP2017535610A5 true JP2017535610A5 (cg-RX-API-DMAC7.html) 2018-09-27
JP6637988B2 JP6637988B2 (ja) 2020-01-29

Family

ID=56014367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545520A Active JP6637988B2 (ja) 2014-11-18 2015-05-11 Rna送達のためのイオン化可能カチオン性脂質

Country Status (20)

Country Link
EP (1) EP3221293B1 (cg-RX-API-DMAC7.html)
JP (1) JP6637988B2 (cg-RX-API-DMAC7.html)
KR (1) KR102380363B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207428A (cg-RX-API-DMAC7.html)
AU (1) AU2015350561B2 (cg-RX-API-DMAC7.html)
CA (1) CA2968060C (cg-RX-API-DMAC7.html)
DK (1) DK3221293T3 (cg-RX-API-DMAC7.html)
ES (1) ES2946110T3 (cg-RX-API-DMAC7.html)
FI (1) FI3221293T3 (cg-RX-API-DMAC7.html)
HK (1) HK1244479A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20230342T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062130T2 (cg-RX-API-DMAC7.html)
IL (1) IL252291B (cg-RX-API-DMAC7.html)
LT (1) LT3221293T (cg-RX-API-DMAC7.html)
NZ (1) NZ732777A (cg-RX-API-DMAC7.html)
PL (1) PL3221293T3 (cg-RX-API-DMAC7.html)
PT (1) PT3221293T (cg-RX-API-DMAC7.html)
RS (1) RS64078B1 (cg-RX-API-DMAC7.html)
SI (1) SI3221293T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016081029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014348212C1 (en) 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2015153780A1 (en) 2014-04-02 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
KR20240172763A (ko) 2016-12-14 2024-12-10 리간달 인코포레이티드 핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
WO2018119163A1 (en) * 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018183901A1 (en) * 2017-03-30 2018-10-04 The Government Of The United States Of America As Represented By The Secretary Of The Army Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines
US12083224B2 (en) 2018-03-30 2024-09-10 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
CN112153985B (zh) 2018-04-25 2024-03-01 埃泽瑞斯公司 用于颗粒制剂的防冻剂
KR20190127277A (ko) * 2018-05-04 2019-11-13 주식회사 삼양바이오팜 mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법
PL3805198T3 (pl) 2018-06-08 2024-02-12 Fujifilm Corporation Związek, jego sól i cząstki lipidowe
JP7445657B2 (ja) 2018-12-06 2024-03-07 アークトゥラス・セラピューティクス・インコーポレイテッド オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法
SG11202110036RA (en) * 2019-03-19 2021-10-28 Arcturus Therapeutics Inc Method of making lipid-encapsulated rna nanoparticles
EP3981435B1 (en) 2019-06-07 2023-08-16 FUJIFILM Corporation Lipid composition
JP2022550435A (ja) 2019-10-04 2022-12-01 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えaavの改善された治療的使用のための方法
DK4328309T3 (da) 2019-11-15 2025-08-18 Fujifilm Corp Lipidsammensætning
JP2023516676A (ja) 2020-03-03 2023-04-20 アークトゥラス・セラピューティクス・インコーポレイテッド オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
CN115667531A (zh) 2020-03-24 2023-01-31 世代生物公司 非病毒DNA载体和其用于表达戈谢(Gaucher)治疗剂的用途
WO2021257917A1 (en) * 2020-06-18 2021-12-23 Arcturus Therapeutics, Inc. Una oligomers for the treatment of polyglutamine diseases
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
IL301253A (en) 2020-09-13 2023-05-01 Arcturus Therapeutics Inc As a mass of large RNA lipid nanoparticles
WO2022173531A1 (en) 2021-02-10 2022-08-18 Oncorus, Inc. Compounds, compositions, and methods of using thereof
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CA3216585A1 (en) 2021-04-27 2022-11-03 Nathaniel SILVER Non-viral dna vectors expressing therapeutic antibodies and uses thereof
IL309505A (en) 2021-09-03 2024-02-01 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20250027108A1 (en) 2021-10-29 2025-01-23 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
EP4463475A2 (en) 2022-01-14 2024-11-20 Anjarium Biosciences AG Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
EP4469091A1 (en) 2022-01-28 2024-12-04 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN114213295B (zh) * 2022-02-22 2022-05-20 中国科学院基础医学与肿瘤研究所(筹) 一种阳离子化合物、制备方法及其复合物和用途
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
US20250345407A1 (en) 2022-05-25 2025-11-13 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
CA3258303A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Compositions of lipid nanoparticles and their uses
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024064910A1 (en) 2022-09-23 2024-03-28 Chroma Medicine, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
AU2023375897A1 (en) 2022-11-08 2025-06-12 Orna Therapeutics, Inc. Circular rna compositions
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
JP2025541726A (ja) 2022-12-01 2025-12-23 ジェネレーション バイオ カンパニー 細胞標的化のためのステルス脂質ナノ粒子組成物
KR20250129819A (ko) 2022-12-01 2025-08-29 제너레이션 바이오 컴퍼니 핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
DE112024001143T5 (de) 2023-03-08 2025-12-18 CureVac SE Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
CN116270543B (zh) * 2023-05-19 2023-09-26 清华大学 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
US20250381150A1 (en) 2024-03-08 2025-12-18 Genzyme Corporation Lipid nanoparticles
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE21633T1 (de) 1981-06-04 1986-09-15 Pharmasol Corp Druckbehaelter mit abgabepumpe.
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US9408914B2 (en) * 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
ES2570184T3 (es) * 2011-06-08 2016-05-17 Nitto Denko Corp Compuestos para dirigir la administración de fármacos y potenciar la actividad de ARNip
WO2013086373A1 (en) * 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2876148C (en) * 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
AU2014348212C1 (en) * 2013-11-18 2018-11-29 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery

Similar Documents

Publication Publication Date Title
JP2017535610A5 (cg-RX-API-DMAC7.html)
JP2015501833A5 (cg-RX-API-DMAC7.html)
RU2015151202A (ru) Композиции и способы модулирования экспрессии hbv и ttr
JP2014508753A5 (cg-RX-API-DMAC7.html)
Liepelt et al. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases
JP2011517683A5 (cg-RX-API-DMAC7.html)
JP2014513954A5 (cg-RX-API-DMAC7.html)
JP2015504067A5 (cg-RX-API-DMAC7.html)
JP2014510729A5 (cg-RX-API-DMAC7.html)
RU2013142448A (ru) Новые сульфонаминохинолиновые антагонисты гепсидина
JP2013509429A5 (cg-RX-API-DMAC7.html)
WO2015081133A3 (en) Nucleotides for the treatment of liver cancer
ES2668045T3 (es) Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
JP2015180657A5 (cg-RX-API-DMAC7.html)
JP2017515901A5 (cg-RX-API-DMAC7.html)
JP2018135343A5 (cg-RX-API-DMAC7.html)
JP2011526924A5 (cg-RX-API-DMAC7.html)
JP2017527532A5 (cg-RX-API-DMAC7.html)
JP2008195730A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2017510610A5 (cg-RX-API-DMAC7.html)
JP2012502048A5 (cg-RX-API-DMAC7.html)
JP2015512943A5 (cg-RX-API-DMAC7.html)
JP2009536660A5 (cg-RX-API-DMAC7.html)
JP2013508279A5 (cg-RX-API-DMAC7.html)